RNA-based Therapeutics and Vaccines Market Value to Surpass $1.24 billion by 2034, With a CAGR of 21.3% [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Rockville, July 04, 2024 (GLOBE NEWSWIRE) -- Fact.MR, in a new research report, states that the global RNA-based therapeutics and vaccine market size is estimated at $180.5 million in 2024 and is evaluated to expand swiftly at a CAGR of 21.3%, to reach a valuation of $1.24 billion from 2024 to 2034. The growing demand for RNA-based therapeutics and vaccines is driven by their remarkable potential and the urgent need for innovative solutions in the healthcare sector. As the world confronts emerging infectious diseases, genetic disorders, and the evolving medical landscape, the versatility and rapid development capabilities of RNA-based technologies have captured the attention of researchers, pharmaceutical companies, and investors alike. For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10213 Success of these vaccines has sparked interest in exploring RNA-based solutions for a broad spectrum of diseases, ran
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Pipeline Moves: Alnylam's Amvuttra approval prospects up after Phase III win [Yahoo! Finance]Yahoo! Finance
- Three Undervalued Stocks With Intrinsic Discounts Ranging From 33.2% To 39.6% [Yahoo! Finance]Yahoo! Finance
- An Intrinsic Calculation For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Suggests It's 50% Undervalued [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $160.00 to $248.00. They now have a "neutral" rating on the stock.MarketBeat
- Three Value Stocks With Discounts Ranging From 18.9% To 43.5% Below Intrinsic Estimates [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 5/2/24 - Beat
ALNY
Sec Filings
- 7/5/24 - Form SC
- 6/27/24 - Form 4
- 6/26/24 - Form 4
- ALNY's page on the SEC website